Literature DB >> 15136705

State-specific projections through 2025 of Alzheimer disease prevalence.

L E Hebert1, P A Scherr, J L Bienias, D A Bennett, D A Evans.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15136705     DOI： 10.1212/01.wnl.0000123018.01306.10

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  33 in total

1.  Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease.

Authors:  Hisham Qosa; Alaa H Abuznait; Ronald A Hill; Amal Kaddoumi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Structural brain changes in normal individuals with a maternal history of Alzheimer's.

Authors:  Valentina Berti; Lisa Mosconi; Lidia Glodzik; Yi Li; John Murray; Susan De Santi; Alberto Pupi; Wai Tsui; Mony J De Leon
Journal:  Neurobiol Aging       Date:  2011-02-12       Impact factor: 4.673

Review 3.  Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging.

Authors:  Lisa Mosconi; Valentina Berti; Lidia Glodzik; Alberto Pupi; Susan De Santi; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies.

Authors:  Alaa H Abuznait; Hisham Qosa; Belnaser A Busnena; Khalid A El Sayed; Amal Kaddoumi
Journal:  ACS Chem Neurosci       Date:  2013-02-25       Impact factor: 4.418

5.  Cerebrovascular disease: Assessing the brain as an end-organ of vascular disease.

Authors:  Charles DeCarli
Journal:  Nat Rev Cardiol       Date:  2012-06-26       Impact factor: 32.419

Review 6.  Clinically asymptomatic vascular brain injury: a potent cause of cognitive impairment among older individuals.

Authors:  Charles DeCarli
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  AAC to support conversation in persons with moderate Alzheimer's disease.

Authors:  Melanie Fried-Oken; Charity Rowland; Darlene Daniels; Mayling Dixon; Bret Fuller; Carolyn Mills; Glory Noethe; Jeon Small; Kevin Still; Barry Oken
Journal:  Augment Altern Commun       Date:  2012-12       Impact factor: 2.214

8.  Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes.

Authors:  Jing He; Sarah Farias; Oliver Martinez; Bruce Reed; Dan Mungas; Charles Decarli
Journal:  Arch Neurol       Date:  2009-11

Review 9.  Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults.

Authors:  Daniel M I Britt; Gregory S Day
Journal:  Mo Med       Date:  2016 May-Jun

10.  Role of synucleins in Alzheimer's disease.

Authors:  Leslie Crews; Igor Tsigelny; Makoto Hashimoto; Eliezer Masliah
Journal:  Neurotox Res       Date:  2009-06-24       Impact factor: 3.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.